Victory Capital Management’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60.1K Sell
21,005
-213
-1% -$654 ﹤0.01% 2417
2026
Q2
$64.5K Buy
21,218
+6,455
+44% +$19.3K ﹤0.01% 2371
2026
Q1
$45.5K Buy
14,763
+2,833
+24% +$12K ﹤0.01% 2317
2025
Q4
$43.1K Buy
11,930
+1,869
+19% +$8.15K ﹤0.01% 2342
2025
Q3
$37.9K Buy
+10,061
New +$38.8K ﹤0.01% 2366
2020
Q2
– Sell
-2,338
Closed -$8K – 2525
2020
Q1
$8K Buy
+2,338
New +$5.38K ﹤0.01% 3137
2019
Q4
– Sell
-2,325
Closed -$5K – 2649
2019
Q3
$5K Hold
2,325
– – ﹤0.01% 3441

Other funds holding ALT

Victory Capital Management's ALT Position: Q3 2026 in Review

Victory Capital Management reduced its Altimmune (ALT) stake by 1% in Q3 2026, selling an estimated $654 and leaving 21,005 shares worth $60.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2417.

Victory Capital Management first reported a position in ALT in Q3 2019 and has held it in 7 quarters since. The position peaked at $64.5K in Q2 2026. 191 funds tracked by Wall St. Rank hold ALT as of Q3 2026.

  • Victory Capital Management held 21,005 shares of Altimmune worth $60.1K as of Q3 2026.
  • Victory Capital Management sold 213 Altimmune shares in Q3 2026, an estimated $654.
  • Altimmune made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #2417 holding.
  • Victory Capital Management first reported a position in Altimmune in Q3 2019 and has held it in 7 quarters since.
  • Victory Capital Management's Altimmune position peaked at $64.5K in Q2 2026.
  • 191 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.